- In April 2024, RemeGen Co., Ltd., a China-based biopharmaceutical company, announced the expansion of its global clinical trials for disitamab vedotin, an HER2-targeted ADC, into Southeast Asia and Australia. This move aims to accelerate regulatory approvals across Asia-Pacific and reflects the company’s strategic focus on expanding access to next-generation cancer therapeutics. RemeGen’s initiative highlights the region’s rising involvement in global oncology development and its growing importance in the ADC innovation ecosystem
- In March 2024, Japan’s Daiichi Sankyo entered into a research and licensing agreement with Singapore-based A*STAR’s Genome Institute to explore novel ADC payloads and linker technologies. The collaboration focuses on enhancing the therapeutic window of existing ADCs and creating more targeted therapies for solid tumors. This development underscores the increasing trend of cross-border collaborations in the Asia-Pacific region aimed at advancing oncology research and drug development
- In February 2024, South Korea’s Samsung Biologics announced its expansion into contract development and manufacturing of ADCs, positioning itself as a key regional player in ADC production. With growing demand for outsourced biopharmaceutical manufacturing in Asia-Pacific, this expansion enhances the scalability of ADC supply chains and supports regional biotech firms in bringing novel therapies to market faster and more cost-effectively
- In February 2024, India's Biocon Biologics signed an exclusive partnership agreement with a U.S.-based biotech firm to co-develop and commercialize a pipeline of ADCs targeting gynecological and gastrointestinal cancers. The partnership is aligned with Biocon’s strategic goal to expand its oncology portfolio and leverage India’s growing clinical and manufacturing infrastructure for advanced biologics
- In January 2024, Australia’s Garvan Institute of Medical Research initiated a Phase I clinical trial evaluating a new Trop-2 targeting ADC developed in partnership with a local biotech startup. The trial represents one of the first early-stage ADC studies launched within Australia and reflects the increasing role of local research institutes in advancing targeted cancer therapies tailored to regional patient populations
